Genomic characterization, transcriptome analysis, and pathogenicity of the Nipah virus (Indian isolate).


Journal

Virulence
ISSN: 2150-5608
Titre abrégé: Virulence
Pays: United States
ID NLM: 101531386

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 19 6 2023
pubmed: 14 6 2023
entrez: 14 6 2023
Statut: ppublish

Résumé

Nipah virus (NiV) is a high-risk pathogen which can cause fatal infections in humans. The Indian isolate from the 2018 outbreak in the Kerala state of India showed ~ 4% nucleotide and amino acid difference in comparison to the Bangladesh strains of NiV and the substitutions observed were mostly not present in the region of any functional significance except for the phosphoprotein gene. The differential expression of viral genes was observed following infection in Vero (ATCC® CCL-81™) and BHK-21 cells. Intraperitoneal infection in the 10-12-week-old, Syrian hamster model induced dose dependant multisystemic disease characterized by prominent vascular lesions in lungs, brain, kidney and extra vascular lesions in brain and lungs. Congestion, haemorrhages, inflammatory cell infiltration, thrombosis and rarely endothelial syncitial cell formation were seen in the blood vessels. Intranasal infection resulted in respiratory tract infection characterised by pneumonia. The model showed disease characteristics resembling the human NiV infection except that of myocarditis similar to that reported by NiV-Malaysia and NiV-Bangladesh isolates in hamster model. The variation observed in the genome of the Indian isolate at the amino acid levels should be explored further for any functional significance.

Identifiants

pubmed: 37312405
doi: 10.1080/21505594.2023.2224642
pmc: PMC10281463
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2224642

Références

Vector Borne Zoonotic Dis. 2012 Jan;12(1):65-72
pubmed: 21923274
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0005120
pubmed: 27812087
Int J Infect Dis. 2021 Jan;102:144-151
pubmed: 33129964
Structure. 2019 Apr 2;27(4):660-668.e4
pubmed: 30799076
Sci Rep. 2016 Aug 03;6:30916
pubmed: 27484128
Emerg Infect Dis. 2005 Oct;11(10):1594-7
pubmed: 16318702
J Virol. 2004 May;78(10):5358-67
pubmed: 15113915
Sci Rep. 2012;2:736
pubmed: 23071900
Am J Pathol. 2003 Nov;163(5):2127-37
pubmed: 14578210
J Gen Virol. 2006 Dec;87(Pt 12):3649-3653
pubmed: 17098981
Indian J Pathol Microbiol. 2021 Jul-Sep;64(3):621-623
pubmed: 34341295
J Virol. 2006 Dec;80(24):12070-8
pubmed: 17005661
PLoS One. 2018 Aug 2;13(8):e0201827
pubmed: 30071116
J Virol Methods. 2004 Sep 15;120(2):229-37
pubmed: 15288966
Eur J Cell Biol. 2015 Jul-Sep;94(7-9):316-22
pubmed: 26059400
J Infect Dis. 2019 May 24;219(12):1867-1878
pubmed: 30364984
J Immunol Methods. 2011 May 31;368(1-2):24-35
pubmed: 21334343
Nature. 2005 Jul 21;436(7049):401-5
pubmed: 16007075
Nat Struct Mol Biol. 2014 Sep;21(9):754-9
pubmed: 25108352
Emerg Infect Dis. 2006 Feb;12(2):235-40
pubmed: 16494748
J Virol. 2009 Aug;83(16):7828-41
pubmed: 19515782
Emerg Infect Dis. 2011 May;17(5):907-9
pubmed: 21529409
Emerg Infect Dis. 2012 Feb;18(2):248-55
pubmed: 22304936
Front Immunol. 2018 Jun 07;9:888
pubmed: 29930549
Curr Top Microbiol Immunol. 2004;283:61-119
pubmed: 15298168
J Virol. 2006 Aug;80(15):7546-54
pubmed: 16840334
Am J Pathol. 2002 Dec;161(6):2153-67
pubmed: 12466131
Sci Rep. 2020 Oct 26;10(1):18256
pubmed: 33106487
Clin Infect Dis. 2020 Jun 24;71(1):152-157
pubmed: 31627214
FASEB J. 1990 Aug;4(11):2860-7
pubmed: 2199284
BMC Infect Dis. 2021 Feb 9;21(1):162
pubmed: 33563231
Emerg Infect Dis. 2019 May;25(5):1003-1006
pubmed: 31002049
J Virol. 2004 Jun;78(11):5633-41
pubmed: 15140960
J Virol. 2010 Oct;84(19):9793-9
pubmed: 20668089
PLoS Pathog. 2006 Feb;2(2):e7
pubmed: 16477309
J Virol. 2011 Aug;85(15):7658-71
pubmed: 21593160
PLoS Negl Trop Dis. 2013;7(1):e2024
pubmed: 23342177
J Virol. 2005 Jun;79(12):7528-34
pubmed: 15919907
Clin Infect Dis. 2008 Apr 1;46(7):977-84
pubmed: 18444812
J Gen Virol. 2004 Jun;85(Pt 6):1675-1684
pubmed: 15166452
J Virol. 2011 Aug;85(15):7863-71
pubmed: 21593145
J Virol. 2007 Oct;81(19):10804-14
pubmed: 17652392
Lancet. 1999 Oct 9;354(9186):1257-9
pubmed: 10520635
Clin Infect Dis. 2002 May 1;34 Suppl 2:S48-51
pubmed: 11938496
Lancet. 1999 Oct 9;354(9186):1253-6
pubmed: 10520634
Sci Rep. 2018 Oct 30;8(1):15994
pubmed: 30375468
Emerg Infect Dis. 2007 Jul;13(7):1031-7
pubmed: 18214175
J Infect Dis. 2020 May 11;221(Suppl 4):S436-S447
pubmed: 32022850
Emerg Infect Dis. 2015 Feb;21(2):328-31
pubmed: 25626011
J Gen Virol. 2009 Feb;90(Pt 2):392-397
pubmed: 19141448
Virol J. 2008 Nov 10;5:137
pubmed: 19000317
Virol J. 2006 Jun 19;3:47
pubmed: 16784519
Emerg Infect Dis. 2012 Dec;18(12):1983-93
pubmed: 23171621
J Infect Dis. 2020 May 11;221(Suppl 4):S448-S453
pubmed: 31665342

Auteurs

Sreelekshmy Mohandas (S)

Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.

Anita Shete (A)

Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.

Prasad Sarkale (P)

Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.

Abhinendra Kumar (A)

Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.

Chandrasekhar Mote (C)

Department of Veterinary Pathology, Krantisinh Nana Patil College of Veterinary Science, Shirwal, Maharashtra, India.

Pragya Yadav (P)

Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH